A Comparison of Chemotherapy Used with and without Apatinib for Patients with Ovarian Carcinoma Who Progressed after Standard Regimens: A Systematic Review and Meta-Analysis

Table 3

Meta-analysis results of adverse drug reactions (Figures S1–S9).

Outcomes	Number of trials	Experimental group (events/total)	Control group (events/total)	SM	OR (95% CI)	I^2	Heterogeneity	value
Myelosuppression (Figure S1)	5	38/162	36/166	FEM	1.16 (0.61, 2.17)	0%	0.92	0.65
Leucopenia (Figure S2)	5	49/119	54/127	FEM	1.00 (0.56, 1.79)	0%	0.68	0.99
Hypertension (Figure S3)	11	98/339	40/351	REM	3.18 (1.63, 6.20)	53%	0.02	<0.001
Proteinuria (Figure S4)	6	28/148	12/160	FEM	3.14 (1.51, 6.52)	30%	0.21	0.002
Gastrointestinal reaction (Figure S5)	5	80/165	90/173	FEM	0.87 (0.55, 1.37)	0%	0.98	0.54
Nausea/vomiting (Figure S6)	5	40/161	40/161	FEM	1.00 (0.58, 1.73)	0%	0.78	1.00
Hand-foot syndrome (Figure S7)	7	60/201	19/213	REM	4.39 (1.59, 12.15)	55%	0.04	0.004
Liver/renal dysfunction (Figure S8)	4	32/113	38/117	FEM	0.81 (0.46, 1.44)	0%	0.74	0.47
Fatigue (Figure S9)	2	8/54	7/58	FEM	1.23 (0.41, 3.66)	0%	0.48	0.71

Note: SM: statistical method, REM: random-effects model, FEM: fixed-effects model, OR: odds ratio, and CI: confidence interval.